BioNTech und OncoC4 starten zulassungsrelevante Phase-3-Studie mit BNT316/ONC-392-Programm bei metastasiertem, nicht-kleinzelligem Lungenkarzinom
29 juin 2023 06h45 HE
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie für nicht-kleinzelliges Lungenkarzinom ist ein wichtiger erster Schritt in BioNTechs und OncoC4s strategischer Kollaboration, die im März 2023...
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
29 juin 2023 06h45 HE
|
BioNTech SE
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate...
Monoclonal Antibodies Industry Analysis 2023: 180+ Companies, 230+ Drugs, Therapeutics Assessment, Inactive Pipeline Products, Unmet Needs
26 juin 2023 05h03 HE
|
Research and Markets
Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal antibodies - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive...
Antibody Drug Conjugates Market to surpass USD 26.5 billion by 2032, says Global Market Insights Inc.
20 juin 2023 20h00 HE
|
Global Market Insights Inc.
Selbyville, Delaware, June 20, 2023 (GLOBE NEWSWIRE) -- Antibody Drug Conjugates Market size will cross USD 26.5 billion by 2032. Growing advancements in antibody engineering and conjugation...
[Latest] Global Tissue Diagnostics Market Size/Share Worth USD 125.63 Billion by 2032 at a 12.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
14 juin 2023 16h50 HE
|
Custom Market Insights
Austin, TX, USA, June 14, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Tissue Diagnostics Market Size, Trends and Insights By Application (Prostate...
Monoclonal Antibody Discovery and Research Report 2022-2032 - Growing Demand for Monoclonal Antibodies for Cancer Treatments
13 juin 2023 10h38 HE
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Discovery and Analysis Market Report 2022-2032" report has been added to ResearchAndMarkets.com's offering.Overall world revenue...
Global Monoclonal Antibody Partnering Terms and Agreements Trends Report 2023
13 juin 2023 04h58 HE
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibody Partnering Terms and Agreements 2016 to 2023" report has been added to ResearchAndMarkets.com's offering.The Global...
Global Monoclonal Antibody Therapeutics Market Report 2023: Sector is Expected to Reach $534.2 Billion by 2030 at a CAGR of 12.7%
08 juin 2023 06h18 HE
|
Research and Markets
Dublin, June 08, 2023 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Therapeutics Market, By Source, by Application, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity...
Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research
07 juin 2023 13h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 07, 2023 (GLOBE NEWSWIRE) -- The global organ transplant rejection medication market is estimated to flourish at a CAGR of 3.9% from 2023 to 2031. According...
BioNTech und OncoC4 präsentieren positive Phase-1/2-Daten für Antikörperkandidaten BNT316/ONC-392 bei schwer behandelbarem nicht-kleinzelligen Lungenkarzinom auf ASCO-Jahrestagung
02 juin 2023 06h45 HE
|
BioNTech SE
BNT316/ONC-392 ist ein innovativer monoklonaler anti-CTLA-4-Antikörperkandidat, der gemeinsam von BioNTech und OncoC4 als Mono- oder Kombinationstherapie zur Behandlung verschiedener solider...